- Home
- ATIP vs CMMB Comparison
ATIP vs CMMB Comparison
Compare ATIP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIP
- CMMB
- Stock Information
- Founded
- ATIP 1996
- CMMB 2004
- Country
- ATIP United States
- CMMB Israel
- Employees
- ATIP N/A
- CMMB N/A
- Industry
- ATIP Hospital/Nursing Management
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ATIP Health Care
- CMMB Health Care
- Exchange
- ATIP Nasdaq
- CMMB Nasdaq
- Market Cap
- ATIP 26.0M
- CMMB 20.9M
- IPO Year
- ATIP N/A
- CMMB N/A
- Fundamental
- Price
- ATIP $6.24
- CMMB $1.28
- Analyst Decision
- ATIP
- CMMB Strong Buy
- Analyst Count
- ATIP 0
- CMMB 3
- Target Price
- ATIP N/A
- CMMB $5.67
- AVG Volume (30 Days)
- ATIP 7.9K
- CMMB 157.1K
- Earning Date
- ATIP 11-04-2024
- CMMB 11-07-2024
- Dividend Yield
- ATIP N/A
- CMMB N/A
- EPS Growth
- ATIP N/A
- CMMB N/A
- EPS
- ATIP N/A
- CMMB N/A
- Revenue
- ATIP $717,149,000.00
- CMMB N/A
- Revenue This Year
- ATIP $10.99
- CMMB N/A
- Revenue Next Year
- ATIP $5.98
- CMMB N/A
- P/E Ratio
- ATIP N/A
- CMMB N/A
- Revenue Growth
- ATIP 11.00
- CMMB N/A
- 52 Week Low
- ATIP $3.92
- CMMB $0.42
- 52 Week High
- ATIP $8.48
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ATIP 60.27
- CMMB 40.12
- Support Level
- ATIP $5.66
- CMMB $1.09
- Resistance Level
- ATIP $6.46
- CMMB $1.39
- Average True Range (ATR)
- ATIP 0.30
- CMMB 0.17
- MACD
- ATIP 0.01
- CMMB -0.02
- Stochastic Oscillator
- ATIP 72.50
- CMMB 27.54
About ATIP ATI Physical Therapy Inc.
ATI Physical Therapy Inc is a recognized outpatient physical therapy provider in the United States specializing in outpatient rehabilitation and adjacent healthcare services. It offer a variety of services within the clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.